Considerations for treatment duration in responders to immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) have improved overall survival for cancer patients, however, optimal duration of ICI therapy has yet to be defined. Given ICIs were first used to treat patients with metastatic melanoma, a condition that at the time was incurable, little attention was initially pa...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Immunother Cancer
Main Authors: Marron, Thomas U, Ryan, Aideen E, Reddy, Sangeetha M, Kaczanowska, Sabina, Younis, Rania H, Thakkar, Dipti, Zhang, Jiajia, Bartkowiak, Todd, Howard, Rachel, Anderson, Kristin G, Olson, Daniel, Naqash, Abdul Rafeh, Patel, Ravi B, Sachdev, Esha, Rodriguez-Ruiz, Maria E, Sheffer, Michal, Church, Sarah, Fuhrman, Christopher, Overacre-Delgoffe, Abigail, Nguyen, Rosa, Florou, Vaia, Thaxton, Jessica E, Aggen, David H, Guerriero, Jennifer L
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2021
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7929825/
https://ncbi.nlm.nih.gov/pubmed/33653801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001901
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki